Gmt Capital Corp Opti Nose, Inc. Transaction History

Gmt Capital Corp

$2.45 Billion
Q3 2024

A detailed history of Gmt Capital Corp transactions in Opti Nose, Inc. stock. As of the latest transaction made, Gmt Capital Corp holds 1,110,702 shares of OPTN stock, worth $466,494. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,110,702

Previous 1,110,702 -0.0%

Holding current value

$466,494

Previous $1.16 Million 35.58%

% of portfolio

0.03%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.82 - $1.44 $910,775 - $1.6 Million	1,110,702 New	1,110,702 $1.16 Million
Q4 2023 Feb 12, 2024	SELL	$1.02 - $1.47 $887,180 - $1.28 Million	-869,785 Reduced 78.31%	240,917 $310,000
Q2 2023 Aug 10, 2023	BUY	$1.11 - $2.05 $1.21 Million - $2.23 Million	1,087,414 Added 4669.42%	1,110,702 $1.37 Million
Q1 2023 May 09, 2023	BUY	$1.63 - $2.02 $37,959 - $47,041	23,288 New	23,288 $44,000
Q2 2021 Aug 13, 2021	BUY	$2.91 - $3.83 $2.85 Million - $3.75 Million	979,820 Added 748.63%	1,110,702 $3.45 Million
Q1 2021 May 13, 2021	SELL	$3.47 - $4.75 $9.76 Million - $13.4 Million	-2,814,039 Reduced 95.56%	130,882 $483,000
Q2 2020 Aug 14, 2020	BUY	$3.58 - $7.44 $8.23 Million - $17.1 Million	2,299,518 Added 356.29%	2,944,921 $21.9 Million
Q1 2020 May 13, 2020	BUY	$3.49 - $9.2 $2.25 Million - $5.94 Million	645,403 New	645,403 $2.9 Million
Q4 2019 Feb 14, 2020	SELL	$6.27 - $11.41 $1.31 Million - $2.38 Million	-209,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.4 - $10.94 $1.34 Million - $2.29 Million	209,000 New	209,000 $1.48 Million

Others Institutions Holding OPTN

# of Institutions

Shares Held

88.3M

Call Options Held

Put Options Held

View Full List

About OptiNose, Inc.

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $35M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

More about OPTN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Gmt Capital Corp with notifications on news.

Account